🇺🇸 FDA
Patent

US 10265337

Use of A3 adenosine receptor agonist in osteoarthritis treatment

granted A61KA61K31/00A61K31/519

Quick answer

US patent 10265337 (Use of A3 adenosine receptor agonist in osteoarthritis treatment) held by CAN-FITE BIOPHARMA LTD. expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CAN-FITE BIOPHARMA LTD.
Grant date
Tue Apr 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/00, A61K31/519, A61K31/706, A61K31/7076